Aaron M. Goodman
University of California, San Diego
CancerInternal medicinePathologyOncologyCell-free fetal DNAImmunologyMultiple myelomaImmunotherapyBlockadeDiseaseLymphomaMEDLINEImmune checkpointIn patientMutationCancer researchClinical trialText miningMedicineBiomarker (medicine)BiologyImmune system
81Publications
21H-index
2,417Citations
Publications 92
Newest
#1Rahul Banerjee (UCSF: University of California, San Francisco)H-Index: 6
#2Shonali Midha (Harvard University)
Last. Ghulam Rehman Mohyuddin (UofU: University of Utah)H-Index: 5
view all 6 authors...
Source
#1Ronald S. Go (Mayo Clinic)H-Index: 51
#2Eric D. Jacobsen (Brigham and Women's Hospital)H-Index: 38
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 21
view all 25 authors...
Histiocytic neoplasms are rare hematologic disorders accounting for less than 1% of cancers of the soft tissue and lymph nodes. Clinical presentation and prognosis of these disorders can be highly variable, leading to challenges for diagnosis and optimal management of these patients. Treatment often consists of systemic therapy, and recent studies support use of targeted therapies for patients with these disorders. Observation ("watch and wait") may be sufficient for select patients with mild di...
Source
Source
Abstract null Background null Methods that enable monitoring of therapeutic efficacy of autologous chimeric antigen receptor (CAR) T-cell therapy will be clinically useful. null Objectives null The aim of this study is to demonstrate the feasibility of blood-derived cell-free DNA (cfDNA) to predict CAR T-cell therapy response in patients with refractory B-cell lymphomas. null Study design null Whole blood was collected prior to and throughout CAR T-cell therapy until day +154. Low-coverage (∼0.4...
Source
#1Timothy V. Pham (UCSD: University of California, San Diego)H-Index: 4
#2Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 21
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 137
view all 5 authors...
Background null Tumor mutational burden (TMB) may be a predictive biomarker of immune checkpoint inhibitor (ICI) responsiveness. Genomic landscape heterogeneity is a well-established cancer feature. Molecular characteristics may differ even within the same tumor specimen and undoubtedly evolve with time. However, the degree to which TMB differs between tumor biopsies within the same patient has not been established. null Methods null We curated data on 202 patients enrolled in the PREDICT study ...
Source
#1Ghulam Rehman Mohyuddin (UofU: University of Utah)H-Index: 5
#2Tahani Atieh (KU: University of Kansas)
Last. Vinay Prasad (UCSF: University of California, San Francisco)H-Index: 39
view all 10 authors...
Abstract null null Introduction null Chimeric antigen receptor T-cell therapy (CART) has revolutionised treatment of haematological malignancies; however, current reporting uses a modified intention-to-treat analysis (mITT) which over-estimates efficacy. null We assessed what proportion of CD19 and B-cell maturation antigen (BCMA) CART trials report the number of patients not receiving CART after being enrolled by performing meta-analysis of the mITT and intention-to-treat (iTT) overall response...
Source
#1Ghulam Rehman Mohyuddin (UofU: University of Utah)H-Index: 5
#2Rahul Banerjee (UCSF: University of California, San Francisco)H-Index: 6
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 21
view all 3 authors...
Source
#1Elli D. Novatcheva (UCSD: University of California, San Diego)
#2Yasmine Anouty (UCSD: University of California, San Diego)
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 21
view all 5 authors...
Acute myeloid leukemia (AML) is the most common acute leukemia of adults, with a five-year survival that remains poor (approximately 25%). Knowledge and understanding of AML genomics have expanded tremendously over the past decade and are now included in AML prognostication and treatment decisions. FMS-like tyrosine kinase 3 (FLT3) is a Class III receptor tyrosine kinase (RTK) expressed primarily in the cell membranes of early hematopoietic progenitor cells, found in 28% of all patients with AML...
Source
When tissue biopsy is not medically prudent or tissue is insufficient for molecular testing, alternative methods are needed. Because cell-free DNA (cfDNA) has been shown to provide a representative surrogate for tumor tissue, we sought to evaluate its utility in this clinical scenario. cfDNA was isolated from the plasma of patients and assayed with low-coverage (∼0.3×), genome-wide sequencing. Copy-number alterations (CNA) were identified and characterized using analytic methods originally devel...
Source
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 21
#2Ah-Reum Jeong (UCSD: University of California, San Diego)H-Index: 1
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 137
view all 9 authors...
Objectives null Castleman disease (CD) is a heterogeneous group of disorders involving systemic inflammation and lymphoproliferation. Recently, clonal mutations have been identified in unitcentric CD (UCD) and idiopathic multicentric CD (iMCD), suggesting a potential underlying neoplastic process. null Methods null Patients with UCD or iMCD with next generation sequencing (NGS) data on tissue DNA and/or circulating tumor DNA (ctDNA) were included. null Results null Five patients were included, 4...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.